The European Commission granted marketing authorization for Janssen’s Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant.
Thousand Oaks, California-based Amgen significantly expanded the company’s presence in China by taking a 20.5 percent stake in BeiGene Co.
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Despite concerns about potential competition from recently approved and available European biosimilars to Humira, AbbVie was able to stave off some of the losses expected during Q2 2019.
Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.
Shares of Karyopharm Therapeutics skyrocketed more than 36 percent after the U.S. Food and Drug Administration approved the Newton, Mass.-based company’s Xpovio for treating multiple myeloma.
The U.S. Food and Drug Administration lifted a partial clinical hold placed on AbbVie’s Phase III CANOVA trial evaluating venetoclax for the treatment of relapsed/refractory multiple myeloma.
Weekend Highlights from 2019 ASCO Annual Meeting
American Society of Clinical Oncology (ASCO), Analysis, Approvals, Clinical Data, Clinical Trials, Endocrine Therapy, Epidermal Growth Factor Receptor (EGFR), FDA, Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Monoclonal Antibodies, Oncology, R&D, Relapse/Refractory Multiple Myeloma, Stage III non-small cell lung cancer (NSCLC), UnresectableThere was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.
Celgene Corporation announced that the European Commission approved two new triplet regimens based on the company’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide).
